Johnson & Johnson reinforces its leadership in neuropsychiatry, presenting pivotal data for seltorexant and aticaprant at the 2024 APA and ASCP meetings.
Charles River Laboratories First Quarter 2026 Results were officially released, showcasing a company in the midst of a significant strategic transformation. The Wilmington-based contract research [Read More…]
Understanding how hantavirus spreads is the first critical step in protecting yourself and your family from a rare but highly dangerous respiratory disease. Whether you are cleaning out an old barn, sweeping a dusty attic, or opening up a long-closed summer cabin, knowing the risks associated with rodent-borne pathogens can quite literally save your life. Hantaviruses are primarily excreted in the urine, droppings, and saliva of infected wild rodents, and most human infections occur when these substances are disturbed and become airborne, allowing microscopic viral particles to be easily inhaled.
Gilead Sciences reports a strong Q1 2026 with $6.96 billion in revenue, driven by its industry-leading HIV portfolio and the rapid uptake of Yeztugo, despite acquisition-related guidance adjustments.
Released in May 2026, the Novo Nordisk Q1 2026 report showcases a complex but optimistic financial picture, highlighting a massive revenue beat fueled by the record-breaking U.S. launch of the Wegovy pill, prompting the pharmaceutical giant to raise its full-year guidance.
Eli Lilly has released historic long-term data from the Omvoh mirikizumab-mrkz clinical trials, proving that the IL-23p19 antagonist maintains high rates of “disease clearance” through four years of treatment.
Pfizer has reported its first-quarter 2026 earnings, exceeding market expectations with $14.5 billion in revenue. The company reaffirmed its full-year guidance, bolstered by a 22% operational growth in launched and acquired products.
Amgen has reported a robust start to the year, with its Q1 2026 financial results exceeding analyst estimates. Total revenue climbed to $8.6 billion, driven by double-digit growth across 16 key brands and a promising expansion of the MariTide obesity program.
The recent STELARA FDA approval provides a crucial new non-TNF biologic treatment option for children two years and older suffering from moderately to severely active Crohn’s disease.
Eli Lilly and Company’s Q1 2026 results showcased a 56% revenue surge to $19.8 billion, driven by unparalleled demand for its incretin portfolio and breakthrough oncology treatments.
